SNP Genotypes and Technology of the Effective Genes Analysis; Recommendations for Cardiology
Journal Title: Biomedical Journal of Scientific & Technical Research (BJSTR) - Year 2017, Vol 1, Issue 1
Abstract
Each patient has a combination of the genes bound to cardiovascular illnesses. Today there are 3000 illnesses to which individual genetic tests (Gene Tests Med. Gen. Information Resource 2013) are available. However to interpret such results, for example for polygenic diseases as an essential hypertension without computer systems is extremely difficult. Usually it is bound to a larger flow of information and shortage of clinical geneticists. Besides cognitive abilities of the cardiologist are limited by lack of knowledge in the field of bioinformatics and biotechnology. Differences between genomic and clinical tests Unprecedented depreciation of the chip-sequencing, made possible to conduct large researches of cardiovascular diseases. These technologies were always followed by 2 main problems: I. choice of management of a huge array of genomic data; II. choice of computing methods of the analysis [1-3]. Despite it, use of genomic results for 10 years became ubiquitous. Technically genetic tests don’t differ from any other medical test. Genomic tests as all other clinical tests, are caused by the probabilistic size where a certain path physiological state is present (that is the diagnosis), or will be present (that is, the forecast) [4]. Anyway, genomic or usual tests are used for clinical decision-making in the context of an asymptomatic or pathological condition of the patient. As a result clinical genomic data have the same purpose as other medical tests: to provide information at diagnosis and treatment of the patient. However, genetic tests have also some difference from clinical: a. high probability of the unforeseen obtained data; b. confidentiality of the obtained information (only for family members); c. The obtained data don’t guarantee that the patient understands character of the provided information (for example: this category includes information on future risks of development of pathologies). Today there are some doubts that highly technological genetic tests of SNP won’t be more expensive than medical researches [5]. Today the most important difference between genomic tests and clinical - the fact that medical institutions and medical industrial infrastructure believe that genetic and usual medical tests will be very different because of complexity of interpreting results.
Authors and Affiliations
Aleksandr Nagay, Kurbanov RD, Khamidullaeva GA, Srojidiniva NZ, Tursunova NB
Keywords
Related Articles
- EP ID EP567213
- DOI 10.26717/BJSTR.2017.01.000128
- Views 171
- Downloads 0
Muscle Weakness and Gait Disturbance due to Side Effects of Benzodiazepine Long Term Administration, Causes Mental Health Problems
Benzodiazepines (BZO) are frequently used as anxiolytics and hypnotics in daily clinical treatment. However it should be noticed that long term usage of BZO may disturb activity of daily life (ADL) and cause unexpectedly...
Upper Crossed Syndrome and Dentistry Why the Need for Concern
Occupational hazard plays a detrimental role in influencing the quality and quantity of work of dental health care personnel. Basic understanding of the same is essential in terms of improved productivity and progress. A...
Browning the Epicardial Adipose Tissues in Cardiovascular Regulation
Epicardial adipose tissue (EAT) is located between the myocardium and the visceral layer of pericardium. EAT is characterized by increased rate of fatty acid metabolism and increased expression of thermogenic genes. EAT...
Man in Outer Space without Space Suite
The author proposes and investigates his old idea - a living human in space without the encumbrance of a complex space suit. Only in this condition can biological humanity seriously attempt to colonize space because all...
Postural Training in Age-Related Macular Degeneration Subjects: Issues and Impact
Age-related macular degeneration (AMD) is the leading cause of visual impairment and blindness after fifty years old in developed countries [1,2]. It is estimated AMD will affect 288 million of elderly in 2040 [3]. This...